华恒生物(688639) - 2023 Q1 - 季度财报
AHBAHB(SH:688639)2023-04-25 16:00

Financial Performance - The company's revenue for Q1 2023 reached ¥400,254,753.80, representing a year-on-year increase of 48.02%[4] - Net profit attributable to shareholders was ¥81,198,285.24, up 47.03% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥78,316,720.65, reflecting a growth of 45.97% year-on-year[4] - Basic and diluted earnings per share were both ¥0.75, marking a 47.06% increase[5] - Total operating revenue for Q1 2023 reached RMB 400,254,753.80, a 48% increase from RMB 270,406,890.76 in Q1 2022[18] - Net profit for Q1 2023 was RMB 81,188,337.13, representing a 47% increase compared to RMB 55,226,359.00 in Q1 2022[19] - The company reported a total profit of RMB 91,749,530.89 for Q1 2023, compared to RMB 64,567,911.26 in Q1 2022, an increase of 42%[19] Cash Flow and Liquidity - The net cash flow from operating activities amounted to ¥91,795,730.89, an increase of 34.41% from the previous year[4] - Cash flow from operating activities for Q1 2023 was RMB 91,795,730.89, compared to RMB 68,295,013.05 in Q1 2022, indicating a 34% increase[21] - The company achieved a total cash inflow from operating activities of RMB 427,308,791.69 in Q1 2023, compared to RMB 282,774,582.93 in Q1 2022, a 51% increase[21] - The net increase in cash and cash equivalents was $139,683,066.02, compared to $23,322,972.34 in the previous year, showing strong liquidity improvement[22] - Total cash and cash equivalents at the end of the period reached $286,656,669.32, up from $143,170,460.96 year-over-year[22] Research and Development - R&D investment totaled ¥24,726,169.10, which is 80.70% higher than the previous year, accounting for 6.18% of revenue[5] - Research and development expenses for Q1 2023 totaled RMB 24,726,169.10, significantly higher than RMB 13,683,732.27 in Q1 2022, reflecting a 81% increase[18] - The company plans to continue increasing R&D investment to support future growth[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,193,805,895.60, an increase of 8.22% from the end of the previous year[5] - The company's current assets totaled CNY 922,247,802.36, up from CNY 863,055,449.61, indicating an increase of about 6.83%[15] - Total liabilities increased to CNY 625,737,074.28 from CNY 545,440,388.40, which is an increase of about 14.69%[16] - The company's equity attributable to shareholders reached CNY 1,566,927,509.52, up from CNY 1,480,494,149.53, representing a growth of approximately 5.83%[17] Investment Activities - Net cash flow from investment activities was -$66,009,054.97, compared to -$61,460,609.14 in the previous year, indicating a decline in investment performance[22] - Cash inflow from investment activities totaled $253,204,502.81, compared to $223,432,127.42 in the previous year, reflecting growth in investment receipts[22] - The company did not absorb any new investments in the current quarter, contrasting with $6,000,000.00 received in the previous year[22] Other Financial Metrics - The return on equity (ROE) increased by 2.16 percentage points to 6.72%[5] - Cash and cash equivalents reached CNY 287,146,669.32, compared to CNY 147,463,603.30 in the previous period, reflecting a significant increase of approximately 94.93%[13] - The company's inventory decreased to CNY 124,709,065.65 from CNY 135,513,945.72, showing a decline of about 7.00%[15] - Short-term borrowings rose to CNY 193,894,995.13, compared to CNY 79,227,749.24, marking an increase of approximately 144.49%[16] - The deferred income tax liabilities increased to CNY 65,424,004.06 from CNY 54,052,854.28, reflecting an increase of approximately 21.06%[16] - The company’s retained earnings rose to CNY 802,466,156.08 from CNY 721,267,870.84, showing an increase of about 11.00%[16]